Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials

R. Huber, S. Gettinger, D. -W Kim, L. Bazhenova, K. Hansen, M. Tiseo, C. Langer, L. Paz-Ares Rodriguez, H. West, K. Reckamp, G. Weiss, E. Smit, M. Hochmair, S. -W Kim, M. -J Ahn, E. Kim, H. Groen, J. Pye, F. Vranceanu, D. R. Camidge


Originele taal-2English
Pagina's (van-tot)4-5
Aantal pagina's2
TijdschriftOncology Research and Treatment
StatusPublished - sep.-2021

Citeer dit